医疗科技公司豪洛捷宣布，其Aptima® HPV检测产品已获得美国食品药品监督管理局（FDA）批准，可作为宫颈癌初级筛查方案。这一重要监管突破显著拓展了该公司在宫颈健康领域的产品组合。
此次获批意味着临床医生能够直接采用该检测技术进行宫颈癌初步筛查，为女性健康管理提供更精准高效的解决方案。新产品选项将强化豪洛捷在分子诊断市场的竞争优势，为医疗机构提供更全面的宫颈癌防治工具。
医疗科技公司豪洛捷宣布，其Aptima® HPV检测产品已获得美国食品药品监督管理局（FDA）批准，可作为宫颈癌初级筛查方案。这一重要监管突破显著拓展了该公司在宫颈健康领域的产品组合。
此次获批意味着临床医生能够直接采用该检测技术进行宫颈癌初步筛查，为女性健康管理提供更精准高效的解决方案。新产品选项将强化豪洛捷在分子诊断市场的竞争优势，为医疗机构提供更全面的宫颈癌防治工具。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.